deltatrials
Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03325621

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis

Sponsor: FGK Clinical Research GmbH

Conditions Anemia of Chronic Kidney Disease
Interventions PRS-080#022-DP PRS-080-Placebo#001
Updated 7 times since 2017 Last updated: Oct 17, 2019 Started: Sep 30, 2017 Primary completion: Mar 30, 2019 Completion: Jun 30, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Anemia of Chronic Kidney Disease, this trial is completed. The trial is conducted by FGK Clinical Research GmbH and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Nov 2017 – ~Jun 2018 · 7 months · monthly snapshotRecruiting~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshotRecruiting~Dec 2018 – ~Nov 2019 · 11 months · monthly snapshotRecruiting~Nov 2019 – ~Jan 2021 · 14 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1_PHASE2

  4. Nov 2019 — Jan 2021 [monthly]

    Completed PHASE1_PHASE2

    Status: Recruiting → Completed

  5. Dec 2018 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE1_PHASE2

  2. Nov 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • FGK Clinical Research GmbH
  • Pieris Pharmaceuticals GmbH
Data source: Pieris Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations